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Short Title 
Placental insufficiency: an orphan disease 
On behalf of the EVERREST Consortium
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Abstract  
Objective To determine whether a novel therapy for placental insufficiency could achieve 
orphan drug status by estimating the annual incidence of placental insufficiency, defined 
as an estimated fetal weight below the 10th centile in the presence of abnormal umbilical 
artery Doppler velocimetry, per 10,000 European Union (EU) population as part of an 
application for European Medicines Agency (EMA) orphan designation 
Design Incidence estimation based on literature review and published national and EU 
statistics 
Setting and Population European Union 
Methods Data were drawn from published literature, including national and international 
guidelines, international consensus statements, cohort studies and randomised controlled 
trials, and published national and EU statistics, including birth rates and stillbirth rates. 
Rare disease databases were also searched. 
Results The proportion of affected pregnancies was estimated as 3.17% (95% CI 2.93% to 
3.43%), using a weighted average of the results from two cohort studies. Using birth rates 
from 2012 and adjusting for a pregnancy loss rate of 1/100 gave an estimated annual 
incidence of 3.33 per 10,000 EU population (95% CI 3.07 to 3.60 per 10,000 EU 
population). This fell below the EMA threshold of 5 per 10,000 EU population.  
Conclusions Maternal vascular endothelial growth factor gene therapy for placental 
insufficiency was granted EMA orphan status in 2015 after we demonstrated that it is a 
rare, life-threatening or chronically debilitating and currently untreatable disease. 
Developers of other potential obstetric therapies should consider applying for orphan 
designation, which provides financial and regulatory benefits. 
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European Union Seventh Framework Programme (FP7/2007-2013) grant agreement no. 
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Tweetable Abstract 
Placental insufficiency meets the European Medicines Agency requirements for orphan 
disease designation. 
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1. Introduction  
For many years, the development of new obstetric therapies has been hampered by 
underinvestment from the pharmaceutical industry.1-5 One way to address this is to 
consider whether new therapies qualify for orphan drug designation.6 Orphan drug 
legislation was originally introduced in the United States in 1983 to encourage the 
development of medicines for rare diseases that might otherwise be financially unviable. 
Since then the European Union (EU), Australia, Singapore, Japan, Taiwan and South Korea 
have introduced their own legislation.7-9  
The criteria for what constitutes a rare disease and the benefits that orphan drug 
designation bring vary between regulatory authorities. To qualify for European Medicines 
Agency (EMA) orphan designation a medicine must meet three key conditions (Table 1).9, 10  
The application for orphan status is made by the sponsor, either a commercial company or 
an academic institution (Figure S1).11 If orphan status is granted the sponsor has access to 
EMA scientific advice at a reduced cost and receives 10 years of protection from market 
competition if the medicine is approved for use (Table S1).12 Orphan drug designation can 
also be granted for repurposing licenced drugs. Successful applications bring the same 
benefits, but a separate application for marketing authorisation must be made for the rare 
disease indication using a different proprietary name.13 
Despite the potential benefits, obstetric therapies are drastically under-represented 
among orphan drug designations. As of February 2018, the EMA had granted 1952 orphan 
drug designations and the US Federal Drug Agency (FDA) 4473. Of these, only 15 drugs are 
for the prevention or treatment of problems arising during pregnancy and only one, 
hydroxyprogesterone caproate, has been approved for use (Table 2). 
The EVERREST consortium is an industrial academic health science partnership funded by 
the European Commission which aims to develop a new treatment for placental 
insufficiency manifesting as fetal growth restriction (FGR).14 This treatment proposes to 
use maternal uterine artery application of an adenovirus gene therapy containing Vascular 
Endothelial Growth Factor (VEGF) to increase uteroplacental perfusion via reduced uterine 
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artery contractility and to increase local angiogenesis.15  In January 2015 one of the 
industrial partners, backed by the rest of the EVERREST consortium, successfully applied 
for EMA orphan drug designation for the use of maternal VEGF gene therapy to treat 
placental insufficiency.  
In this article we outline how we estimated the annual incidence of placental insufficiency 
per 10,000 EU population. We believe that these methods could be applied to other 
obstetric diseases to form part of future successful orphan drug designation applications. 
2. Methods 
2.1. Defining the rare disease for orphan drug designation 
Within the original title of the EVERREST Project, maternal VEGF gene therapy is described 
as a potential treatment for Òsevere early-onset fetal growth restrictionÓ. However, EMA 
guidance states that the rare disease which the medicinal product will treat, prevent or 
diagnose should be Òa distinct medical entity with specific pathological, histopathological 
or clinical characteristicsÓ.16  
The terms FGR and intrauterine growth restriction (IUGR) have been used inconsistently 
and interchangeably over the years, most often to describe a fetus with an estimated fetal 
weight (EFW) <10th centile17 or a fetus that has failed to achieve its growth potential.18, 19 
Small-for-Gestational Age (a definition based on a size or weight below a given threshold 
of the distribution, typically the 10th centile) has also been used as a proxy of FGR, adding 
more confusion. FGR is not a distinct disease but is instead a syndrome that can result 
from maternal, fetal and placental factors, alone or in combination. This made FGR 
unsuitable for our  rare disease, since a therapy which increases uterine artery volume 
flow would not be expected to improve FGR resulting from causes such as aneuploidy. 
In research and clinical practice, the shift from syndrome to disease is often made by 
defining a subset of FGR, for example FGR presenting before 32 weeks of gestation in the 
absence of fetal structural or chromosomal anomalies. However, for the purposes of 
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orphan drug designation the EMA will generally not accept a subset of patients as a rare 
disease. Therefore, we needed to determine a suitable disease term with appropriate 
diagnostic criteria for our orphan drug application.  
We searched national and international guidelines and consensus statements for 
definitions of FGR, and for alternative diagnostic terms and definitions. A PubMed search 
was performed for consensus development conferences, guidelines, and practice 
guidelines (search terms, automatically including alternate spellings, field terms and MeSH 
terms: Òfetal growth restrictionÓ Òfetal growth retardationÓ Òintrauterine growth 
restrictionÓ Òintrauterine growth retardationÓ ÒplacentaÓ, limits: article type ÒConsensus 
Development ConferenceÓ OR ÒGuidelineÓ OR ÒPractice GuidelineÓ). The National 
Guideline Clearing House and International Guideline Library were searched for all 
guidelines relating to fetal growth restriction. Full lists of the current guidelines of the 
Royal College of Obstetricians and Gynaecologists (RCOG), the American Congress of 
Obstetrics and Gynecology (ACOG) and the Society of Obstetricians and Gynaecologists of 
Canada (SOGC) were reviewed. We hand-searched the International Statistical 
Classification of Diseases and Related Health Problems 10th Revision (ICD-10) for relevant 
terms and potential definitions. As a reflection of current international opinion on 
diagnostic criteria we searched ClinicalTrials.gov and the ISRCTN Registry using the term 
Ògrowth restrictionÓ and reviewed the inclusion criteria for any relevant multicentre 
trials. Final decisions were made through expert consensus within the EVERREST 
Consortium via face-to-face meetings and e-mail correspondence. 
2.2. Estimating the annual incidence of placental insufficiency 
For EMA orphan designation a condition should have a prevalence of not more than five 
per 10,000 of the EU population. For conditions lasting less than a year, for example those 
occurring only during pregnancy, the annual incidence must be less than five per 10,000 of 
the EU population. In estimating the annual incidence of obstetric conditions it is 
necessary to consider the proportion of pregnancies that are affected, the proportion of 
pregnancies which do not end in live birth, and national and EU birth rates.  
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2.2.1.Estimating the proportion of pregnancies affected by placental insufficiency 
A literature search was conducted for epidemiological analyses of conditions and terms 
associated with placental insufficiency. Medline was searched using the terms Òumbilical 
DopplerÓ AND ÒFGRÓ OR Òfetal growth restrictionÓ OR Òfetal growth retardationÓ OR 
ÒIUGRÓ OR Òintrauterine growth restrictionÓ OR Òintrauterine growth retardationÓ OR 
Òsmall for gestational ageÓ. Pubmed was searched using the terms Òprevalence 
uteroplacental insufficiencyÓ, Òprevalence placental insufficiencyÓ, Òfrequency 
uteroplacental insufficiencyÓ, Òfrequency placental insufficiencyÓ, Òbirth cohort 
ÔultrasoundÕÓ, and Òbirth cohort DopplerÓ. No restriction was made on the language of the 
publication.  
Studies were not included if they looked at first and second trimester prediction, or if 
they included only pregnancies with abnormal umbilical Doppler examination, for example 
to investigate outcomes. Studies were excluded if they did not use the 10th centile for 
EFW and/or birth weight, considered only low EFW and/or birth weight or abnormal 
umbilical artery Doppler examination rather than a combination of the two, did not 
provide sufficient data to allow calculation of the proportion of affected pregnancies, or 
did not sample from a general obstetric population. Studies were included if part of the 
inclusion criteria for the study was the presence of a small-for-gestational age (SGA) fetus, 
as long as this was not also limited to pregnancies considered high- or low-risk. 
The references of relevant studies, review articles, and national guidelines were searched 
by hand, including the Cochrane reviews of umbilical artery Doppler use in high-risk20 and 
normal pregnancy21, and theRCOG ÒGreen-top Guideline No.31 The Investigation and 
Management of the Small-for-Gestational-Age FetusÓ.18 Databases from the National 
Organization for Rare Disorders (NORD)22, Orphanet23, the Genetic and Rare Disease 
Information Centre (GARD)24, and the Swedish Information Centre for Rare Diseases25 were 
searched. The search terms were ÔplacentaÕ, ÔplacentalÕ, ÔinsufficiencyÕ and ÔpregnancyÕ.  
2.2.2.Calculating annual incidence in relation to the population of the European 
Union 
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The annual incidence was estimated by considering the proportion of pregnancies which 
the literature suggested would be affected (p), the number of potentially affected 
pregnancies over one year (n), and the size of the European Community population (pop), 
where: 
Annual incidence = (p x n)/pop 
National and European statistics for birth rate give the number of live births per year (b) 
per 1000 population: 
   Birth rate = (1000 x b)/pop 
However, the number of potentially affected pregnancies (n) needs to include not only live 
births but also pregnancies which could have been affected but ended in termination, 
miscarriage or stillbirth. If we add in an inflation factor (i) to account for these 
pregnancies then: 
   Annual incidence per 10,000 = p x 10 x birth rate x i 
2.2.3.Estimating the proportion of potentially affected pregnancies which do not 
end in live birth 
Since placental insufficiency cannot be diagnosed in the first trimester we did not need to 
adjust for pregnancies ending in miscarriage or termination in the first trimester. In order 
to correct for later pregnancy loss we reviewed national and European statistics on 
termination of pregnancy, miscarriage and stillbirth. Further data on elective termination 
of pregnancy in severe early-onset placental insufficiency was acquired through local 
retrospective audit and further data on pregnancy loss rates was obtained by searching 
Medline using the terms ÒFetal deathÓ[MeSH or All fields] OR ÒAbortion, 
SpontaneousÓ[MeSH] OR ÒStillbirthÓ[MeSH or All fields] OR Òfetal lossÓ AND 
ÒIncidenceÓ[MeSH] OR ÒCohort StudiesÓ[MeSH] OR ÒetiologyÓ AND ÒPregnancy Trimester, 
SecondÓ[MeSH] OR Òsecond trimesterÓ. 
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2.3. Patient involvement and core outcome sets 
There was no public or patient involvement in this work nor were core outcome sets used. 
2.4. Funding  
The research leading to these results has received funding from the European Union 
Seventh Framework Programme (FP7/2007-2013) under grant agreement no. 305823. This 
research has been supported by the National Institute for Health Research University 
College London Hospitals Biomedical Research Centre (RS, ALD, DMP). The funders played 
no role in conducting the research or writing the manuscript. 
3. Results  
3.1.Defining the disease for an orphan designation 
We decided that the term Ôplacental insufficiencyÕ best reflected the distinct medical 
condition which maternal VEGF gene therapy aimed to treat. We defined the diagnostic 
criteria as an estimated fetal weight (EFW) below the 10th centile in the presence of 
abnormal umbilical artery Doppler examination, including a pulsatility index (PI) above the 
95th centile, absent end-diastolic flow (EDF) and reversed end-diastolic flow.  
Placental insufficiency is recognised within the ICD 10 classification 036.5: Òmaternal care 
for poor fetal growth due to placental insufficiencyÓ.  It is also recognised and described 
by national guidelines; in the context of a fetus with an EFW below the 10th centile the 
ACOG states that Òincreased impedance in the umbilical artery suggests that the 
pregnancy is complicated by underlying placental insufficiencyÓ17, while the SOGC states 
that ÒDoppler studies of the uterine and umbilical arteries, together with ultrasound 
assessment of placental morphology, may be used to establish a diagnosis of placental 
insufficiencyÓ.19 An EFW or AC <10th centile with absent or reversed EDF formed part of 
the eligibility criteria for the UK trial of Sildenafil therapy in dismal prognosis early-onset 
intrauterine growth restriction (STRIDER, ISRCTN39133303) while an AC <10th and umbilical 
artery PI >95th centile constituted IUGR in the Trial of Umbilical and Foetal Flow in Europe 
(TRUFFLE, ISRCTN56204499). 
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Since our successful orphan drug application an International consensus definition of FGR 
has been published, which includes within its definition of early FGR an EFW <10th centile 
with an umbilical artery PI >95th centile.26 
3.2. Annual incidence of placental insufficiency 
3.2.1.The proportion of pregnancies affected by placental insufficiency 
Three published studies were identified from which it was possible to estimate the 
proportion of pregnancies affected by placental insufficiency (Table 3).27-29 A further 11 
studies were assessed for eligibility but not included in the incidence estimate, either 
because they did not use a general obstetric population30-34, because they used measures 
of size other than an EFW <10th centile30, 33, 35-39 or because they used alternative 
measurements or thresholds to assess the umbilical artery Doppler velocimetry30, 31, 33, 36-38, 
40 (Table S2, Figure S241). The only database to return a relevant finding under any of the 
search terms was GARD, which includes the category Ôplacenta disordersÕ. Within this 
category no further definition was given and no information on prevalence or incidence 
was included. 
The proportion of affected pregnancies was estimated using a weighted average of the 
results from the studies by Unterscheider et al.27 and Figueras et al.28. The results of the 
third study by Davies et al. were considered less reliable because the ultrasound 
technology available at that time may have led to an underestimation of affected 
pregnancies; these results were therefore excluded.29 Using the Wald method to calculate 
the 95% confidence intervals gave an estimate for the proportion of affected pregnancies 
of 3.17% (95% CI 2.93% to 3.43%).  
3.2.2.Accounting for pregnancies which do not end in live birth 
Although national statistics were available for the number of pregnancies ending in 
elective termination each year, the majority of these terminations were before 20 weeks 
of gestation, at a point when placental insufficiency would not be diagnosed. For 
example, in England and Wales in 2013 only 2753 terminations were carried out at or after 
20 weeks of gestation, less than 0.004% of the 698,512 live births for that year.42 It was 
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agreed, therefore, that pregnancies ending in elective termination should not be 
considered as part of the total number of potentially affected pregnancies. 
National statistics were also available for the rates of stillbirth or late fetal death per 
1000 live births, equating to between 0.33 and 0.49% of pregnancies. However, there was 
considerable national variation in how these terms were defined (Table S3). No national 
statistics were available for pregnancies ending earlier in gestation or with a smaller fetal 
size than that defined as stillbirth or late fetal death.  
In turning to the literature, the best quality data came from a cohort of 264,653 women 
screened for DownÕs syndrome in Ontario, Canada between October 1995 and September 
2000.43 1632 of these pregnancies (0.62%) ended in spontaneous fetal loss after 15 weeks 
of gestation. However, since older and smaller studies had reported up to 1.1% of 
pregnancies ending in fetal loss in the second or third trimesters44, 45, we decided to take 
a conservative estimate of 1%, giving an inflation factor of 100/99. 
3.2.3.Annual incidence in relation to the population of the European Union 
Using the estimated proportion of affected pregnancies, national and EU birth rates from 
2012 and an inflation factor of 100/99, we estimated the annual incidence of placental 
insufficiency per 10,000 population (with 95% confidence intervals) for the 28 countries in 
the EU at the time of our application in 2015 and for the European Union as a whole 
(Figure 1). The estimated annual incidence was 3.33 per 10,000 EU population (95% CI 3.07 
to 3.60 per 10,000 EU population), which fell below the EMA threshold of five per 10,000 
EU population.  
Differences in national birth rates, however, led to considerable variation in annual 
incidence between countries. At the request of the EMA we performed additional 
sensitivity analyses to explore the potential effect of a changing birth rate or a rise in the 
proportion of pregnancies affected by placental insufficiency. These showed that the 
estimated annual incidence of placental insufficiency only rose above five per 10,000 EU 
population with a 55% or more rise in the EU birth rate or with 4.8% or more of 
pregnancies being affected.  
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4. Discussion  
4.1. Main Findings 
We have demonstrated that placental insufficiency meets the EMA criteria for a rare 
disease, with an estimated annual incidence of 3.33 per 10,000 EU population. This 
highlights that obstetric diseases do not necessarily have to be ÔrareÕ in pregnancy (i.e. 
<5/10,000 pregnancies) in order to qualify as being rare on a population basis. 
4.2. Additional requirements for EMA orphan drug designation 
In order to be granted EMA orphan drug designation not only must the disease targeted be 
rare but it must also be life-threatening or chronically debilitating. Furthermore, the 
sponsor must justify the medical plausibility of the drug in question. 
In the case of placental insufficiency, the risks of fetal or neonatal death or long-term 
disability for the fetus were easy to demonstrate. Histological studies have found that 
placental insufficiency contributes to between 22% and 49% of stillbirths.46-48 Babies who 
survive a pregnancy complicated by placental insufficiency have long-term effects 
resulting from small size, often combined with iatrogenic preterm delivery, which creates 
a high risk of neonatal morbidity and mortality. The TRUFFLE study looked at the outcomes 
for 503 fetuses diagnosed with placental insufficiency between 26 and 32 weeks gestation.
49 Twelve fetuses (2.4%) died in utero, and a further 27 infants (5.4%) died during their 
time on the neonatal intensive care unit. Overall 24% of surviving infants experienced 
severe morbidity, including bronchopulmonary dysplasia, Grade III or IV germinal matrix 
haemorrhage, Grade II or III cystic periventricular leukomalacia, necrotising enterocolitis, 
or proven sepsis. At 2-year follow-up 10% of the children assessed (39/402) showed 
evidence of neurodevelopmental impairment.50 
Of particular importance to the EMA was the potential impact of placental insufficiency on 
the pregnant woman. This included the potential for Caesarean section, including classical 
Caesarean section, and the resulting increase in maternal morbidity and mortality.18, 46, 51, 
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52 The EMA also considered the psychological impact on the mother of stillbirth or neonatal 
death53 and the potential for co-existing pre-eclampsia. 
The medical plausibility for maternal VEGF gene therapy is based on the observation that 
reduced uterine blood flow is a key pathology in placental insufficiency54, 55, and that 
manipulation of VEGF expression can improve uterine blood flow, increase uterine artery 
relaxation and endothelial nitric oxide synthase (eNOS) production, and increase local 
angiogenesis.56, 57 In preclinical animal models we have previously shown that local 
maternal VEGF gene transfer to the utero-placental circulation using adenovirus vectors 
increases uterine blood flow, attenuates constriction of the uterine arteries and increases 
angiogenesis58; these changes result in improved growth of severely growth restricted 
fetuses.59-62 
4.3. Strengths and Limitations 
Our work provides an insight into a route which so far few obstetric researchers have 
taken. Maternal VEGF gene therapy is one of only five obstetric therapies to receive EMA 
orphan drug designation. We hope that explaining the process and benefits of applying for 
orphan drug designation will encourage other academic and industry researchers to 
consider it.  
It is important to note that our study only provides an estimate for the number of affected 
pregnancies in the EU. Our calculations involve a number of assumptions and our estimate 
for the proportion of affected pregnancies is based on the weighted average of only two 
studies. The relative scarcity of applicable studies in part reflects the heterogeneity in the 
criteria used in the literature to identify FGR and assess placental function.  
For researchers in the United Kingdom (UK) there is also uncertainty about how EMA 
orphan drug designation will apply after the UKÕs exit from the EU. According to Article 2 
of Regulation (EC) No 141/2000 the sponsor of an orphan medicinal product designation, 
whether a commercial company or an academic institution, must be established in the 
European Economic Area (EEA). In June 2018, all UK holders of orphan drug designation 
were advised to transfer designation to a holder established in the EEA.63 
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Orphan drug legislation alone will not overcome all the challenges involved in developing 
new obstetric therapies. In order to consider orphan drug designation, there must be a 
drug to test and licence. This stage on the translational pathway can only be reached once 
the pathophysiology of the condition has been elucidated and a potential therapeutic 
target identified. In recent years attention has turned to careful phenotyping of the three 
great obstetric syndromes, FGR, pre-eclampsia and preterm labour, to help pick apart the 
different underlying causes.64, 65 More work is still needed in this area however, especially 
since the current heterogeneity within these three ÔdiseasesÕ also complicates the design 
and conduct of clinical trials for obstetric therapies. This, in turn, increases the risk that a 
pharmaceutical company will not see a return on their investment and so deters their 
participation in the field.4, 66  
4.4. Interpretation 
In obstetrics, the first orphan drug designations were for prevention of preterm birth in 
1994 and for treatment of severe hypertension associated with pre-eclampsia in 2004 
(Table 2). Subsequently there have been a further ten successful applications, but none 
for placental insufficiency or FGR. The reason for this may be the apparent heterogeneity 
of the condition and the lack of knowledge about the correct calculation of the incidence 
of placental insufficiency as a rare disease. 
5. Conclusion 
Current levels of investment in obstetric therapies are not proportionate to the degree of 
unmet clinical need. Orphan drug designation could offset some of the costs of developing 
obstetric therapies, rendering them more financially attractive for investors. By sharing 
knowledge and experience, and through international multidisciplinary collaboration such 
as is seen in the EVERREST EU FP7 consortium, clinical academics, researchers, investors 
and industry will play a vital role in advancing the field of obstetric research. We hope 
that our successful application for orphan drug designation can provide an example to 
support future applications for maternal and fetal therapies. 
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